Introduction
============

Primary hepatic carcinoma (PHC) is one of the most common malignancies in China ([@b1-ol-0-0-10908]). An estimated 466,000 new PHC cases, and 422,000 PHC-associated mortalities occurred in China in 2015, with only 10% of patients surviving \>5 years ([@b2-ol-0-0-10908]). Furthermore, due to the lack of sensitive markers for early diagnosis, only 10--20% of patients with PHC are suitable for surgical resection, local ablation and other potential therapies ([@b3-ol-0-0-10908]). The current biomarkers that are used for the auxiliary diagnosis of PHC include alpha fetoprotein (AFP), AFP-L3 isoform ratio, glypican-3, des-γ-carboxy-prothrombin, golgi protein 73 and alpha L-fucus glycosidase. However, these markers, even when utilized together, are not sufficient for the identification or early diagnosis of PHC. It is therefore necessary to identify novel early diagnostic markers and therapeutic targets for use in liver cancer diagnosis and treatment ([@b4-ol-0-0-10908]).

Abnormal tumor-suppressor gene inactivation or oncogene activation are leading causes of liver cancer, and a growing number of studies have indicated that circular RNAs (circRNAs) are associated with a variety of cellular activities ([@b5-ol-0-0-10908]). circRNAs are a large class of endogenous, non-coding RNAs that feature covalently closed continuous loops with highly conserved sequences; they have been revealed to serve an important role in the regulation of gene expression during and after transcription ([@b6-ol-0-0-10908]). The majority of circRNAs derive from exons, localize in the cytoplasm, and exhibit tissue/developmental stage-specific expression ([@b7-ol-0-0-10908]). circRNAs can be detected in human blood samples and exhibit higher expression levels than corresponding linear mRNAs ([@b8-ol-0-0-10908]). As previously reported, circRNAs have been demonstrated to serve a role in the occurrence and progression of a variety of tumor types, including esophageal squamous cell and basal cell carcinoma, as well as colon, ovarian and breast cancers ([@b9-ol-0-0-10908]--[@b13-ol-0-0-10908]). These studies clearly demonstrate the potential use of circRNAs as tumor biomarkers ([@b14-ol-0-0-10908]--[@b16-ol-0-0-10908]). It has recently been reported that hsa_circ_0001649, hsa_circ_0005075, hsa_circ_0000130, hsa_circ_0004018 and hsa_circ_0001445 may represent potential biomarkers for hepatocellular carcinoma (HCC), and potentially influence PHC tumor occurrence and metastasis ([@b17-ol-0-0-10908]--[@b21-ol-0-0-10908]). circRNAs act as a sponge for microRNAs (miRNAs), regulating downstream mRNA genes through a competing endogenous RNA (ceRNA) network ([@b22-ol-0-0-10908]). Compared with miRNAs and long non-coding RNAs, circRNAs have not been extensively researched in HCC, with only a few studies focusing on their differential expression in liver cancer tissues. However, to the best of our knowledge, their expression in plasma has not yet been determined, and the use of ceRNA networks and their potential application in clinical diagnosis are yet to be elucidated.

In the present study, comprehensive circRNA expression profiles were analyzed in PHC tissues and paired adjacent normal tissues using circRNA chip screening. Differentially expressed (DE) circRNAs were further validated in PHC tissues and plasma samples using reverse transcription-quantitative (RT-q) PCR. Significant downregulation of hsa_circ_0003056 in PHC tissues and hsa_circ_0067127 in plasma was demonstrated. The ceRNA networks of hsa_circ_0003056 and hsa_circ_0067127 were constructed and analyzed using gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses.

Materials and methods
=====================

### Patients and specimens

A total of 14 PHC tissue specimens and paired adjacent normal tissues, along with fresh plasma samples from 35 PHC patients and 32 healthy donors, were obtained between October 2016 and August 2018 at The Second Hospital of Nanjing (Nanjing, China). Non-tumorous tissues were removed 2.0 cm from the tumor edge and no obvious malignant cells were identified by a pathologist. Following dissection, all tissues were preserved in RNA storage solution (Shanghai SangonBiotech Co., Ltd.) and stored at −80°C until further use. All tissues were confirmed by pathological examination and none of the patients received neoadjuvant therapy. The baseline characteristics and clinicopathological features of each patient were collected from the hospital digital health care system, and are summarized in [Table I](#tI-ol-0-0-10908){ref-type="table"}. The research procedures of the present study were approved by the Ethics Committee of the Second Hospital of Nanjing, and written informed consent was obtained from all enrolled participants.

### circRNA expression profiles

A circRNA chip (Arraystar Human circRNAs Array V2; Zhejiang Kangchen Biotech Co., Ltd.) containing 13,617 probes specific to human circRNA splicing sites was used. A total of three pairs of tumor tissues and paired non-tumorous tissues from patients with PHC were analyzed using the circRNA chips, according to the manufacturer\'s protocol. The chips were then scanned using the Agilent Scanner G2505C (Agilent Technologies, Inc.), and the raw data were extracted using Agilent Feature Extraction software (version 11.5.1.1; Agilent Technologies, Inc.). Quantile normalization of the raw data and subsequent data processing were performed using the R software limma package 3.40.6 (<http://www.bioconductor.org/packages/release/bioc/html/limma.html>). Subsequently, low intensity filtering was performed, and circRNAs that appeared in ≥3 out of 6 samples, and had flags in 'P' or 'M' ('All Targets Value') were selected for further analyses. circRNAs that exhibited fold changes ≥1.5 and P≤0.05 were selected as the significant DE circRNAs. circRNA/miRNA interactions were predicted using Arraystar\'s home-made miRNA target prediction software, which was derived by modifying an existing software package from TargetScan ([@b23-ol-0-0-10908]) (<http://www.targetscan.org/>) and miRanda ([@b24-ol-0-0-10908]) (<http://www.microrna.org/microrna/home.do>). The miRNA support vector regression scores were identified and used to construct a 'Top 5' circRNA-miRNA-mRNA network for DE circRNAs.

### Total RNA extraction and RT-qPCR

Total RNA was isolated from tumor tissues, adjacent normal tissues and plasma samples using the AllPure Tissue kit, HiPure Blood/Liquid RNA kit (Magen; <http://www.magentec.com.cn/>) and miRNeasy Serum/Plasma kit (Qiagen, GmbH) according to the manufacturers\' protocols. The total RNA was quantified using a Colibri spectrometer (Titertek Berthold), and RNA integrity was assessed using electrophoresis on a denaturing agarose gel. Isolated RNA samples were stored at −80°C prior to use. Total RNA from tissue (1.0 µg) or plasma (0.3 µg) was reverse transcribed into first-strand cDNA using the HiScript Q RT SuperMix for qPCR (+gDNA wiper; Vazyme) according to the manufacturer\'s protocol. qPCR was performed using the SYBR^®^ Green Master Mix (High ROX Premixed; Vazyme), with the Applied Biosystems™ QuantStudiot™ 3 Real-Time PCR system (Thermo Fisher Scientific, Inc.). circRNAs were analyzed with β-actin as the internal standard. The reactions were prepared as follows: 10 µl qPCR SYBR^®^ Green Master Mix (High Rox Premixed), 0.4 µl forward primer (10 µM), 0.4 µl reverse primer (10 µM), 8.2 µl RNase free water and 1 µl cDNA. The thermocycling conditions were as follows: 95°C for 5 min, followed by 40 cycles of 95°C for 10 sec and 60°C for 30 sec, and a final step of 95°C for 15 sec, 60°C for 60 sec and 95°C for 15 sec. All primers used in the present study were designed and synthesized by Geneseed Biotech Co., Ltd. and are listed in [Table II](#tII-ol-0-0-10908){ref-type="table"}.

### Functional enrichment analyses and ceRNA network construction

GO term enrichment analysis (<http://www.geneontology.org>) covers three domains: Biological process (BP), cellular component (CC) and molecular function (MF). KEGG pathway enrichment analyses were conducted using the Database for Annotation, Visualization and Integrated Discovery 6.8 ([@b25-ol-0-0-10908]), and the P-value (EASE-score, Fisher-P-value or Hypergeometric-P-value) denotes the significance of the pathway when correlated with the conditions. miRNAs that target circRNAs were predicted by surveying for 7-mer or 8-mer complementarity to seed region and the 3′ pairing of each miRNA using TargetScan. For humans and mice, two databases were used to predict the target genes of miRNAs: TargetScan 7.1 (<http://www.tatgetscan.org/vert_71/>) and mirdb V5 (<http://mirdb.org/miRDB>). The overlapping results of the two databases for humans and mice were accepted. The miRNA-target interactions were then experimentally validated using the database miraTarbase 7.0 (<http://mirtarbase.mbc.nctu.edu.tw/php/index.php>).

### Statistical analysis

Statistical analyses were performed using SPSS version 12.0 (SPSS, Inc.), GraphPad Prism version 5.0 (GraphPad, Inc.) and Cytoscape 2.8.1 (<https://cytoscape.org/>). Data of the relative expression of circRNAs were analyzed using the 2^−ΔΔCq^ method ([@b26-ol-0-0-10908]) and presented as the mean ± standard deviation. Paired or unpaired Student\'s t-tests were used to compare continuous variables in tissue and plasma samples. An unpaired Student\'s t-test was used for stratified analyses according to the clinicopathological features of patients with PHC. P\<0.05 was considered to indicate a statistically significant result.

Results
=======

### Identification of DE circRNAs in PHC tissues using circRNA chip screening

The expression patterns of circRNAs were determined using circRNA chip screening in three pairs of PHC tissues and adjacent non-tumorous tissues. Following microarray scanning and normalization, significant changes were observed. A total of 155 circRNAs were indicated to be DE in PHC tissues (80 upregulated and 75 downregulated), compared with the paired non-tumorous tissues ([Table III](#tIII-ol-0-0-10908){ref-type="table"}). A differential gene expression hierarchical cluster heat map of circRNA expression patterns clearly distinguished PHC tissues from paired adjacent normal tissues ([Fig. 1A](#f1-ol-0-0-10908){ref-type="fig"}). In the volcano plot, green and red dots indicate the down- and upregulation of circRNAs expression in PHC tissues, respectively ([Fig. 1B](#f1-ol-0-0-10908){ref-type="fig"}).

### Confirmation of DE circRNAs in PHC tissues using RT-qPCR

To confirm the differential expression of circRNAs (indicated by circRNA microarray screening), RT-qPCR was performed to assess the expression levels of five candidate DE circRNAs in PHC tissues, compared with adjacent normal tissues, derived from an additional 11 patients with PHC. The five circRNAs (two upregulated and three downregulated) were selected according to the following criteria: i) Fold-change \>1.5; ii) P\<0.05; iii) exonic-related circRNAs; iv) raw intensity ≥100; v) included in circBase; and vi) exhibiting a gene symbol or miRNA binding sites that were considered to be significantly associated with tumor occurrence. Only circRNAs that exhibited a ≥1.5-fold expression level difference were considered to display statistically significant changes (P\<0.05). Moreover, complete and accurate sequence information, and other information regarding the selected exonic-related circRNAs, were retrieved from circBase. A group raw intensity of ≥100 ensured the reliability of the detected fluorescence values of circRNAs determined using the microassay. Finally, circRNAs may influence PHC development and progression through circRNA-miRNA-mRNA networks. Thus, only circRNAs whose target genes or miRNA binding sites had a predetermined association with cancer progression were preferentially selected.

As exhibited in [Fig. 2A](#f2-ol-0-0-10908){ref-type="fig"}, only hsa_circ_0003056 expression was consistently and significantly lower in PHC tissues when compared with paired adjacent non-tumorous tissues. The other three circRNAs exhibited a fold-change in expression level between 1.5 and 2, which was not significantly different from the adjacent tissues.

### Expression levels and association with clinicopathological parameters of hsa_circ_0003056 and hsa_circ_0067127 in PHC patient plasma

Hsa_circ_0003056 expression levels were decreased in PHC tissues compared with paired, adjacent non-tumor tissues. Hsa_circ_0067127 also exhibited decreased expression levels in PHC tissues, but the difference was not significant compared with the adjacent non-tumorous tissues, which may be due to the small sample size. To determine whether changes in expression level were also reflected in patients\' plasma, fresh plasma samples were collected from an additional 35 patients with PHC, and 32 healthy donors. Subsequently, the expression levels of hsa_circ_0003056 and hsa_circ_0067127 were detected using RT-qPCR. As indicated in [Fig. 2B](#f2-ol-0-0-10908){ref-type="fig"}, no significant downregulation or upregulation of hsa_circ_0003056 was identified in the patients\' plasma, when compared with healthy donor plasma. However, hsa_circ_0067127 was significantly downregulated in the PHC plasma. Stratified analyses of hsa_circ_0003056 and hsa_circ_0067127 levels in the plasma samples of patients with PHC was performed, and is summarized in [Table I](#tI-ol-0-0-10908){ref-type="table"}. Significant downregulation of hsa_circ_0003056 was observed in patients who were \>60 years old compared those \<60 years old. hsa_circ_0067127 levels were also significantly higher in patients with an AFP level \<200 ng/ml. No association was demonstrated between other clinical and laboratory characteristics (including sex and HBsAg level) and hsa_circ_0003056.

Follow-up was carried out for the 35 patients with PHC and the median overall survival (OS) time was 69 months. Survival data were analyzed using the log-rank test and survival curves were generated using the Kaplan-Meier method. Regarding hsa_circ_0003056 expression, the corresponding 35 patients with PHC were separated into an hsa_circ_0003056 low-expression group (\<mean value in healthy donors\' plasma; n=15; OS=69) and hsa_circ_0003056 high-expression group (\>mean value in healthy donors\' plasma; n=20; OS=72). The difference between OS times observed between groups was not statistically significant (data not shown). In terms of hsa_circ_0067127 expression, only 3 out of 35 patients with PHC displayed higher expression in their plasma than the mean value in the healthy donors. As a result, the survival curves could not be analyzed.

### Construction of ceRNA networks of hsa_circ_0003056 and hsa_circ_0067127, and KEGG/GO enrichment analyses

The target miRNAs of hsa_circ_0003056 and hsa_circ_0067127 were identified and ranked based on their mirSVR scores and TargetScan. This indicated that hsa_circ_0003056 and hsa_circ_0067127 serve as miRNA sponges, regulating the ceRNA network. The five top miRNAs were selected to establish circRNA-miRNA-mRNA networks: hsa-miR-211-5p, hsa-miR-204-5p, hsa-miR-9-3p, hsa-miR-2113 and hsa-miR-499a-5p targeting to hsa_circ_0003056 ([Fig. 3A](#f3-ol-0-0-10908){ref-type="fig"}), and hsa-miR-141-5p, hsa-miR-486-5p, hsa-miR-186-3p, hsa-miR-647 and hsa-miR-212-5p targeting to hsa_circ_0067127 ([Fig. 3B](#f3-ol-0-0-10908){ref-type="fig"}). Regarding hsa_circ_0003056, a Venn diagram ([Fig. 4A](#f4-ol-0-0-10908){ref-type="fig"}) indicated that overlapping results common to the two databases were accepted. TargetScan 7.1 and mirdbV5 are used to forecast the target genes of miRNAs. The bar plot presents the enrichment scores \[-log~10~ (P-value)\] of the top 10 significant enrichment pathways. KEGG pathway analysis demonstrated that DE genes were significantly enriched in pathways regulating the pluripotency of stem cells ([Fig. 4B](#f4-ol-0-0-10908){ref-type="fig"}). The bar plot presents the enrichment score \[-log10 (P-value)\] values of the top 10 significant GO enrichments. The hsa_circ_0003056-miRNAs-targets network exhibited a strong association with 'regulation of kinase activity', 'intracellular-' and 'transmembrane-ephrin receptor' activity in BP, CC and MF, respectively ([Fig. 4C](#f4-ol-0-0-10908){ref-type="fig"}). The overlapping results between the two databases were also accepted for hsa_circ_0067127 ([Fig. 4D](#f4-ol-0-0-10908){ref-type="fig"}). DE genes were significantly enriched in the pathways associated with 'ubiquitin-mediated proteolysis' and 'prostate cancer' ([Fig. 4E](#f4-ol-0-0-10908){ref-type="fig"}). The top 10 significant GO enrichments are presented in [Fig. 4F](#f4-ol-0-0-10908){ref-type="fig"}. The hsa_circ_0067127-miRNAs-targets network exhibited a strong association with 'artery morphogenesis activity', 'HOPS complex' and 'transferase activity, transferring acyl groups' in BP, CC and MF, respectively.

### Cytoscape analysis of hsa_circ_0003056- and hsa_circ_0067127-miRNA-target gene interaction networks

Based on hsa_circ_0003056 and hsa_circ_0067127, the networks of five miRNAs with their target mRNAs were constructed. In these networks, green circular nodes represent mRNAs, pink diamond nodes represent miRNAs, gray lines represent those not experimentally validated, and blue lines represent those experimentally validated (miRTarBase 7.0.). [Fig. 5](#f5-ol-0-0-10908){ref-type="fig"} indicates the top five miRNAs targeting to hsa_circ_0003056 and their target mRNAs. The top three mRNAs corresponding to both hsa-miR-211-5p and hsa-miR-204-5p were adaptor related protein complex 1 subunit sigma 2, solute carrier family 37 member 3 and RAB22A, member RAS oncogene family. Similarly, [Fig. 6](#f6-ol-0-0-10908){ref-type="fig"} presents the top five miRNAs targeting to hsa_circ_0067127 and their target mRNAs.

Discussion
==========

It has been determined that circRNAs may influence the initiation and development of a range of different cancer types. Certain circRNAs are enriched in exosomes ([@b16-ol-0-0-10908]), suggesting that they exhibit the potential to function as tumor biomarkers, and may therefore be used to support diagnosis. However, few reports have investigated this with regards to PHC tissues and plasma. The current study provided a comprehensive circRNA profile in three pairs of PHC tissues and adjacent tissues prior to treatment, using circRNA chip screening. A total of five circRNAs were selected for validation of their respective expression levels in both PHC tissues, and adjacent tissues from 11 patients, using RT-qPCR analysis. However, only hsa_circ_0003056 was confirmed to be significantly downregulated in PHC tissues. According to the initial analyses of circRNA chip screening, the gene coding for hsa_circ_0003056 is located on chromosome 22, and the sequence of its best transcript is NM_012399, with a gene symbol of phosphatidylinositol (Ptdins) transfer protein beta (PITPNB). The relatively linear PITPNB stimulates Ptdins-4-phosphate synthesis and signaling in eukaryotic cells ([@b27-ol-0-0-10908]). However, whether PITPNB influences tumor progression is yet to be determined. Therefore, the current study analyzed the associations between circPITPNB and certain clinicopathological parameters. However, the results revealed no significant association, which may be due to the small sample size of 11 cases. Further functional experiments are required to determine the mechanism behind the downregulation of hsa_circ_0003056 expression in PHC tissues.

Using RT-qPCR, hsa_circ_0003056 expression levels were determined in fresh plasma samples retrieved from 35 PHC patients and 32 healthy donors. The expression levels of hsa_circ_0003056 did not significantly decrease in the plasma taken from patients with PHC. This may be due to the fact that most of the plasma samples were collected from patients undergoing interventional therapy, and only a small number were subjected to specimen collection prior to treatment. It has been suggested that interventional therapies may influence the expression levels of hsa_circ_0003056 in the plasma. circRNAs are relatively stable in plasma, however, the total free nucleic acid content of the peripheral blood is low ([@b28-ol-0-0-10908]). There are no stable, internal or precise quantification methods for the determination of these levels. β-actin or GAPDH can be used in plasma or serum ([@b29-ol-0-0-10908]), but they are not ideal internal references due to their instability and high individual variation. Although circRNAs exhibit a degree of tissue specificity, they are expressed in plasma and can be detected. These circRNAs may represent novel potential serum biomarkers. For example, circRNA-284 and miR-221 both exhibit the potential to become diagnostic biomarkers of carotid plaque ruptures and strokes ([@b30-ol-0-0-10908]). In the present study, the expression level of hsa_circ_0067127 was lower in PHC plasma but not in PHC tissue (compared to normal plasma and para-tumor tissues, respectively), and was also associated with AFP level, as determined by stratified analysis. To further validate the expression levels of hsa_circ_0003056 and hsa_circ_0067127 in PHC plasma, the plasmid vector method should be used in future studies as a standard to quantify the two circRNAs, with an increased sample size for improved reliability.

Mechanisms describing the roles of circRNAs in cancer progression have not been clearly elucidated. The primary function of circRNAs is to act as miRNA sponges by forming circRNA-miRNA-mRNA axes ([@b22-ol-0-0-10908]). The circ_0067934/miR-1324/FZD5/b-catenin signaling complexes may serve as a promising therapeutic target for HCC intervention ([@b31-ol-0-0-10908]). Other functions of circRNAs, such as their interaction with RNA-binding proteins and translating proteins, have previously been described ([@b32-ol-0-0-10908]). In the present study, the top five target miRNAs that were indicated to interact with hsa_circ_0003056, were selected based on their mirSVR scores and TargetScan. These were hsa-miR-211-5p, hsa-miR-204-5p, hsa-miR-9-3p, hsa-miR-2113 and hsa-miR-499a-5p. Hsa-miR-211-5p levels in HCC tissues were lower than those in normal tissues, suggesting an inhibitory role in HCC by inhibiting zinc finger E-box-binding protein (ZEB2) expression ([@b33-ol-0-0-10908]). Hsa-miR-211-5p is also associated with renal cell carcinoma, thyroid tumors and triple-negative breast cancer ([@b34-ol-0-0-10908]--[@b36-ol-0-0-10908]). Hsa-miR-204-5p is associated with a variety of malignancies, including HCC and laryngeal squamous cell carcinoma ([@b37-ol-0-0-10908],[@b38-ol-0-0-10908]). Whether hsa-miR-204-5p is associated with PHC progression, through its interaction with hsa_circ_0003056, remains undetermined. A practical method is urgently required to identify specific interactions between miRNAs and circRNAs, currently identified using complicated bioinformatics prediction networks. KEGG pathway analyses revealed that DE genes were significantly enriched in pathways that regulates the pluripotency of stem cells. GO analyses revealed that hsa_circ_0003056 was strongly associated with 'regulation of kinase activity', and 'intracellular and transmembrane-ephrin receptor activity' in BP, CC and MF, respectively, which is consistent with its linear form (PITPNB), a gene encoding a cytoplasmic protein that catalyzes the transfer of phosphatidylinositol and phosphatidylcholine between membranes.

In the future, functional experiments should be performed to further explore the mechanism of circRNA in the regulation of PHC progression. Hepatic carcinoma cell lines with high or low expression levels of hsa_circ_0003056 should be constructed, and used to conduct proliferation and migration experiments. The binding and co-localization of hsa_circ_0003056 with the top five target miRNAs should be confirmed, and the target genes (mRNAs) corresponding to the miRNAs (as shown using GO enrichment analyses) should be quantified.

In summary, hsa_circ_0003056 expression is significantly decreased in PHC tissues, but is relatively stable in plasma. Conversely, hsa_circ_0067127 is downregulated in PHC plasma but not in PHC tissue. The detailed molecular mechanisms by which hsa_circ_0003056 and hsa_circ_0067127 function as miRNA sponges to regulate PHC occurrence and development require further investigation.
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![Differential expression of circRNAs in PHC tissues detected by circRNA chip screening. (A) Hierarchical cluster heat map of the top 27 most upregulated and downregulated circRNAs in PHC tissues, compared with matched adjacent non-tumorous tissues, analyzed using circRNAs Arraystar Chip in six samples. (B) Volcano plot of the differential expression of circRNAs between PHC tissues and paired paracancerous tissues: The vertical blue line corresponds to up- and downregulation (fold change \>1.5). The green dots and red dots indicate down- and upregulated circRNAs in PHC tissues, respectively. Horizontal blue line indicates P\<0.05. circRNA, circular RNA; PHC, primary hepatic carcinoma; T, tumor tissue; P, paired paracancerous tissues.](ol-18-05-5255-g00){#f1-ol-0-0-10908}

![Confirmation of DE circRNAs in PHC tissues and plasma by RT-qPCR. (A) Expression levels of hsa_circ_0003056, hsa_circ_0005090, hsa_circ_0007646, hsa_circ_0064557 and hsa_circ_0067127 were assessed in 11 PHC patients, with comparisons between PHC tissues and adjacent non-tumor tissues conducted using RT-qPCR; (B) Scatter plots display the relative expression of hsa_circ_0003056 and hsa_circ_0067127 in 35 PHC and 32 healthy plasma samples. DE, differentially expressed; circRNA, circular RNA; PHC, primary hepatic carcinoma; RT-q, reverse transcription-quantitative; T, tumor tissue; N, non-tumorous tissues.](ol-18-05-5255-g01){#f2-ol-0-0-10908}

![Virtual prediction of miRNAs targeting hsa_circ_0003056 and hsa_circ_0067127. Target miRNAs of circRNA were predicted by surveying for 7-mer or 8-mer complementarity to the seed region and the 3′ pairing of each miRNA using TargetScan. The top five miRNAs were chosen based on the mirSVR scores for the establishment of ceRNA networks. (A) miRNAs targeting to hsa_circ_0003056; (B) miRNAs targeting to hsa_circ_0067127. miRNA, microRNA; circRNA, circular RNA; ceRNA, competing endogenous RNA.](ol-18-05-5255-g02){#f3-ol-0-0-10908}

![KEGG pathway and GO enrichment analyses based on the ceRNA network of hsa_circ_0003056 and hsa_circ_0067127. (A-C) Analyses based on the ceRNA network of hsa_circ_0003056. Venn diagram of the overlapping results of two databases: (A) TargetScan 7.1 and mirdbV5 were used for human genes to forecast the target genes of miRNAs; (B) The bar plot presents the enrichment scores \[-log10 (P-value)\] of the top 10 significant enrichment pathways of DE genes. GO analyses cover three domains; and (C) the bar plot shows the enrichment scores \[-log10 (P-value)\] of the top 10 significant GO enrichments. (D-F) Analyses based on the ceRNA network of hsa_circ_0067127: (D) Target genes of miRNAs predicted using TargetScan 7.1 and mirdbV5; (E) enrichment scores of the top 10 significant enrichment pathways of DE genes; and (F) top 10 significant GO enrichments. KEGG, Kyoto Encyclopedia of Genes and Genomes; GO, Gene Ontology; ceRNA, competing endogenous RNA; miRNA, microRNA; DE, differentially expressed.](ol-18-05-5255-g03){#f4-ol-0-0-10908}

![Cytoscape analysis of hsa_circ_0003056-miRNAs-target gene interaction networks. Networks of 5 miRNAs with their target mRNAs were constructed, in which green circular nodes represent mRNAs, pink diamond nodes represent miRNAs, gray lines represent not experimentally validated by miRTarBase 7.0, and blue lines represent experimentally validated by miRTarBase 7.0. miRNA, microRNA.](ol-18-05-5255-g04){#f5-ol-0-0-10908}

![Cytoscape analyses of hsa_circ_0067127-miRNAs-target gene interaction networks. Networks of 5 miRNAs with their target mRNAs were constructed, in which green circular nodes represent mRNAs, pink diamond nodes represent miRNAs, gray lines represent not experimentally validated by miRTarBase7.0, blue lines represent experimentally validated by miRTarBase 7.0. miRNA, microRNA.](ol-18-05-5255-g05){#f6-ol-0-0-10908}

###### 

Baseline characteristics of PHC patients and stratified analyses of hsa_circ_0003056 and has_circ_0067127 expression in PHC plasma.

                                 Hsa_circ_0003056   Hsa_circ_0067127               
  ---------------- --- ---- ---- ------------------ ------------------ ----------- ------
  Sex                                                                              
    Male           3   7    27   2.41±0.56          0.66               0.31±0.07   0.08
    Female         0   4    8    1.89±1.12                             0.70±0.25   
  Age, years                                                                       
    \<60           3   11   20   3.13±0.80          0.04               0.40±0.11   0.56
    ≥60            0   0    15   1.17±0.27                             0.30±0.10   
  HBsAg                                                                            
    Negative       0   1    9    1.32±0.44          0.25               0.39±0.16   0.82
    Positive       3   10   26   2.63±0.64                             0.35±0.09   
  Cirrhosis                                                                        
    Negative       1   8    25   1.83±0.67          0.56               0.51±0.16   0.3
    Positive       2   3    10   2.47±0.64                             0.32±0.09   
  AFP, ng/ml                                                                       
    \<200          3   6    24   2.20±0.58          0.78               0.46±0.10   0.05
    ≥200           0   5    11   2.50±0.98                             0.16±0.04   
  Tumor number                                                                     
    Single         3   8    13   3.03±1.16          0.25               0.42±0.14   0.64
    Multiple       0   3    22   1.85±0.39                             0.34±0.09   
  Tumor diameter                                                                   
    \<5 cm         2   6    21   2.14±0.62          0.72               0.40±0.12   0.61
    ≥5 cm          1   5    14   2.51±0.84                             0.32±0.09   
  TNM stage                                                                        
    I--II          3   11   19   2.53±0.83          0.61               0.42±0.12   0.38
    III--IV        0   0    16   2.01±0.47                             0.29±0.09   

HBsAg, hepatitis B virus surface antigen; AFP, alpha fetal protein; SD, standard deviation; TNM, stage is a classification of malignant tumors; T, size or direct extent of the primary tumor; N, degree of spread to regional lymph nodes; M, presence of distant metastasis.

###### 

Primer sequences for reverse transcription-quantitative PCR.

  Primer name        Forward (5′-3′)            Reverse (5′-3′)          Product length   Regulation
  ------------------ -------------------------- ------------------------ ---------------- ------------
  hsa_circ_0003056   atttatcacctaaagagccgt      tcaattccttctccaccac      119 bp           Down
  hsa_circ_0005090   gaggagctcaccatctgcta       gagttgcagatcaccttgtcc    131 bp           Up
  hsa_circ_0007646   ggaatgacttctctccaattttca   aagaactgcaagaccgcaga     152 bp           Up
  hsa_circ_0064557   gccccctttcacaggtgatct      ttctgctccaggcgggcaat     145 bp           Down
  hsa_circ_0067127   gtcctcccaggatctggctg       hcgcagcttcctcactaacagc   127 bp           Down

###### 

Differentially expressed circRNAs.

  CircRNA ID (circBase)   Chromosome   Strand   circRNA type   Gene symbol    P-value     Fold change (FC)   Regulation
  ----------------------- ------------ -------- -------------- -------------- ----------- ------------------ ------------
  hsa_circ_0000745        chr17        \+       Exonic         SPECC1         0.0212245   1.9054513          Up
  \#N/A                   chr1         −        Exonic         PIK3C2B        0.025524    3.1458593          Up
  hsa_circ_0092125        chrX         −        Exonic         G6PD           0.0155316   2.3746559          Up
  hsa_circ_0068293        chr3         \+       Exonic         AP2M1          0.0373273   1.7639796          Up
  hsa_circ_0007693        chr1         −        Exonic         ERI3           0.0404268   1.6569751          Up
  hsa_circ_0025768        chr12        −        Exonic         TMTC1          0.0265629   1.5242278          Up
  hsa_circ_0005075        chr1         −        Exonic         EIF4G3         0.0360363   2.8689281          Up
  hsa_circ_0073030        chr5         −        Exonic         FAM169A        0.0044122   2.731725           Up
  hsa_circ_0008106        chr3         \+       Exonic         LRCH3          0.0472836   2.2037281          Up
  hsa_circ_0001231        chr22        −        Exonic         DMC1           0.0239959   1.9820607          Up
  hsa_circ_0007646        chr4         \+       Exonic         DCUN1D4        0.0433039   1.9509878          Up
  hsa_circ_0008439        chr3         \+       Exonic         LRCH3          0.0402462   1.8599736          Up
  hsa_circ_0028711        chr12        −        Exonic         RAB35          0.0040302   1.6338613          Up
  hsa_circ_0000760        chr17        \+       Overlapping    MLLT6          0.0058239   1.6282967          Up
  hsa_circ_0005873        chr3         \+       Exonic         LRCH3          0.0368806   2.4621779          Up
  hsa_circ_0002563        chr1         \+       Exonic         KIF2C          0.0035669   2.5852184          Up
  hsa_circ_0076522        chr6         \+       Exonic         ABCC10         0.0204543   2.2221132          Up
  hsa_circ_0008719        chr19        −        Exonic         AKT2           0.0326238   1.8104931          Up
  hsa_circ_0011480        chr1         −        Exonic         PHC2           0.0495597   1.5408582          Up
  hsa_circ_0011477        chr1         −        Exonic         PHC2           0.0465285   1.5066423          Up
  hsa_circ_0081626        chr7         \+       Exonic         CUX1           0.0458484   1.5696195          Up
  hsa_circ_0002994        chr17        −        Exonic         ACLY           0.0228593   2.0403136          Up
  hsa_circ_0043101        chr17        −        Exonic         NLE1           0.015046    1.539322           Up
  hsa_circ_0000937        chr19        \+       Exonic         BCKDHA         0.024951    1.8707604          Up
  hsa_circ_0008958        chr1         \+       Overlapping    CIART          0.0002      1.5087793          Up
  hsa_circ_0003209        chr20        \+       Exonic         TPX2           0.0411834   1.5429038          Up
  hsa_circ_0043497        chr17        −        Exonic         MED24          0.0446081   2.4071688          Up
  \#N/A                   chr7         \+       Exonic         AP1S1          0.005098    2.4339844          Up
  hsa_circ_0007328        chr19        \+       Exonic         DOT1L          0.0098403   1.7198141          Up
  hsa_circ_0087080        chr9         −        Exonic         FBXO10         0.0361757   1.6176128          Up
  hsa_circ_0028990        chr12        −        Exonic         KDM2B          0.0075388   1.6618626          Up
  hsa_circ_0001591        chr6         \+       Overlapping    HIST1H4I       0.0229166   1.9052747          Up
  hsa_circ_0060456        chr20        \+       Exonic         MYBL2          0.0131702   2.3768838          Up
  hsa_circ_0017289        chr1         −        Exonic         SMYD3          0.0356072   1.9878667          Up
  hsa_circ_0037409        chr16        \+       Exonic         TSC2           0.0212241   2.4079542          Up
  hsa_circ_0082614        chr7         −        Exonic         KIAA1549       0.0017741   1.5392865          Up
  hsa_circ_0004656        chr16        \+       Exonic         SLC7A6         0.0019672   1.977973           Up
  hsa_circ_0071653        chr5         \+       Exonic         CEP72          0.0224188   1.9589469          Up
  hsa_circ_0003048        chr16        −        Exonic         VAC14          0.0495136   1.7512677          Up
  hsa_circ_0006916        chr5         −        Exonic         HOMER1         0.0127235   2.0032953          Up
  hsa_circ_0050898        chr19        \+       Exonic         ACTN4          0.0383419   2.5628111          Up
  hsa_circ_0069370        chr4         −        Exonic         SEL1L3         0.0033967   1.5398487          Up
  \#N/A                   chr19        \+       Intronic       DHX34          0.0467045   1.766391           Up
  hsa_circ_0089090        chr9         \+       Exonic         NCS1           0.0028527   1.522742           Up
  hsa_circ_0092297        chr2         −        Intronic       SMPD4          0.0208144   1.7537756          Up
  hsa_circ_0051718        chr19        −        Exonic         LIG1           0.006625    1.8456723          Up
  hsa_circ_0011279        chr1         \+       Exonic         SERINC2        0.0451375   1.5002793          Up
  hsa_circ_0088072        chr9         −        Exonic         PTBP3          0.0046249   1.603221           Up
  hsa_circ_0017287        chr1         −        Exonic         SMYD3          0.0350386   1.7546953          Up
  hsa_circ_0005090        chr1         −        Exonic         SMYD3          0.0144482   1.6936278          Up
  hsa_circ_0002688        chr4         \+       Exonic         WHSC1          0.0121876   3.363273           Up
  \#N/A                   chr5         −        Exonic         LPCAT1         0.0447121   1.8767479          Up
  hsa_circ_0006177        chr2         \+       Intronic       AGAP1          0.0084361   1.5176364          Up
  hsa_circ_0002245        chr6         \+       Exonic         CAP2           0.0433245   1.6219694          Up
  hsa_circ_0014754        chr1         −        Exonic         IQGAP3         0.0036918   2.5346514          Up
  hsa_circ_0092324        chr17        −        Intronic       DNAJC7         0.0216354   2.380195           Up
  \#N/A                   chr5         −        Exonic         CDC25C         0.0454826   1.8293722          Up
  hsa_circ_0041008        chr16        −        Exonic         FANCA          0.0127351   1.8125889          Up
  hsa_circ_0055855        chr2         −        Exonic         AFF3           0.0003327   2.8560336          Up
  hsa_circ_0059760        chr20        \+       Exonic         TM9SF4         0.0219282   2.247014           Up
  \#N/A                   chr21        −        Exonic         HSF2BP         0.0387871   1.6720688          Up
  hsa_circ_0043947        chr17        −        Exonic         BRCA1          0.0408289   1.5983177          Up
  \#N/A                   chr4         \+       Exonic         TACC3          0.0080579   3.2048942          Up
  hsa_circ_0001728        chr7         −        Intronic       MCM7           0.0318177   2.2162243          Up
  hsa_circ_0092370        chr1         −        Intronic       DNAJC11        0.0188763   1.8250598          Up
  \#N/A                   chr19        −        Exonic         CADM4          0.0287784   1.8768288          Up
  \#N/A                   chr4         −        Exonic         SEL1L3         0.0412118   1.711422           Up
  hsa_circ_0082688        chr7         −        Exonic         PARP12         0.0259324   1.5632151          Up
  \#N/A                   chr12        \+       Exonic         P2RX4          0.0057199   1.6028692          Up
  hsa_circ_0006893        chr3         −        Exonic         PHC3           0.0133705   1.5220367          Up
  hsa_circ_0082304        chr7         \+       Exonic         NRF1           0.0164259   1.8654058          Up
  hsa_circ_0001196        chr21        −        Exonic         WDR4           0.0471616   2.1165344          Up
  hsa_circ_0068894        chr4         \+       Exonic         WHSC1          0.0476107   3.2029375          Up
  hsa_circ_0087047        chr9         \+       Exonic         ZCCHC7         0.0103933   1.7475255          Up
  hsa_circ_0002071        chr12        −        Exonic         GOLGA3         0.0050376   2.0771037          Up
  hsa_circ_0012166        chr1         \+       Exonic         KIF2C          0.0324916   1.6186238          Up
  hsa_circ_0008777        chr20        −        Exonic         AURKA          0.0376056   1.9286644          Up
  hsa_circ_0005219        chr20        \+       Exonic         STK35          0.0086497   2.0307961          Up
  hsa_circ_0012151        chr1         −        Exonic         ERI3           0.0237599   1.7283688          Up
  hsa_circ_0037526        chr16        \+       Exonic         CCNF           0.0156714   2.1195943          Up
  hsa_circ_0002198        chr6         \+       Exonic         PDE7B          0.0301888   2.2417711          Down
  hsa_circ_0004712        chr6         \+       Exonic         PDE7B          0.0455082   2.5301703          Down
  hsa_circ_0039783        chr16        \+       Exonic         CBFB           0.0005419   2.2404601          Down
  \#N/A                   chr3         −        Intronic       MAGI1          0.0456285   2.1403102          Down
  hsa_circ_0008945        chr14        −        Exonic         NIN            0.017864    1.7247068          Down
  \#N/A                   chr10        −        Exonic         ANK3           0.0335636   2.7176467          Down
  hsa_circ_0003661        chr11        \+       Exonic         ANKRD42        0.0446637   1.7336621          Down
  hsa_circ_0030051        chr13        −        Exonic         ELF1           0.03574     1.731437           Down
  hsa_circ_0000720        chr16        \+       Exonic         PLCG2          0.0304322   1.8390616          Down
  hsa_circ_0089372        chr9         \+       Exonic         ADAMTS13       0.0252263   2.8096697          Down
  hsa_circ_0002089        chr11        \+       Exonic         ARHGEF12       0.0063054   2.7586096          Down
  hsa_circ_0078223        chr6         −        Exonic         LATS1          0.0447052   1.6186692          Down
  \#N/A                   chr5         −        Exonic         MYO10          0.0190623   2.9255358          Down
  hsa_circ_0059071        chr2         \+       Exonic         FARP2          0.0414464   1.5860201          Down
  hsa_circ_0005801        chr10        −        Exonic         TM9SF3         0.0396484   1.6371578          Down
  hsa_circ_0003357        chr10        \+       Exonic         ADD3           0.0499515   1.9810488          Down
  hsa_circ_0069323        chr4         −        Exonic         GPR125         0.0114958   1.9450245          Down
  hsa_circ_0004219        chr8         \+       Exonic         DOCK5          0.009565    3.2333123          Down
  hsa_circ_0002955        chr11        \+       Exonic         ARHGEF12       0.0472601   3.0446992          Down
  hsa_circ_0017248        chr1         −        Exonic         AKT3           0.0481372   1.6202917          Down
  hsa_circ_0042339        chr17        −        Exonic         SHMT1          0.0289513   1.6262584          Down
  \#N/A                   chr2         −        Exonic         SMC6           0.0354823   1.6429599          Down
  hsa_circ_0003056        chr22        −        Exonic         PITPNB         0.0021306   2.1416189          Down
  hsa_circ_0001041        chr2         −        Exonic         EIF2AK3        0.0281227   1.7488955          Down
  hsa_circ_0000550        chr14        \+       Antisense      SLC10A1        0.0143731   2.6344379          Down
  hsa_circ_0003640        chr4         \+       Exonic         METAP1         0.002348    1.8630256          Down
  hsa_circ_0078328        chr6         −        Exonic         SYNE1          0.0220923   1.7778472          Down
  hsa_circ_0036610        chr15        \+       Exonic         PDE8A          0.0491465   1.8214826          Down
  hsa_circ_0005045        chr2         −        Exonic         RTN4           0.0407689   2.1566167          Down
  hsa_circ_0006663        chr16        −        Exonic         LUC7L          0.0277407   1.5172731          Down
  hsa_circ_0073649        chr5         −        Exonic         DTWD2          0.0126395   1.6366199          Down
  \#N/A                   chr13        \+       Exonic         EEF1DP3        0.0365432   1.8802713          Down
  hsa_circ_0067127        chr3         −        Exonic         ALDH1L1        0.0187756   4.2915721          Down
  hsa_circ_0038409        chr16        −        Exonic         LOC100271836   0.0381125   1.731821           Down
  hsa_circ_0071311        chr4         \+       Exonic         KIAA0922       0.007598    2.0057656          Down
  hsa_circ_0002771        chr16        −        Exonic         PARN           0.0286315   1.7820343          Down
  hsa_circ_0005471        chr17        −        Exonic         NCOR1          0.0039017   1.8690309          Down
  hsa_circ_0069244        chr4         −        Exonic         LDB2           0.0246507   2.4543633          Down
  hsa_circ_0015164        chr1         −        Exonic         SLC19A2        0.0118506   1.9309544          Down
  hsa_circ_0006539        chr8         \+       Exonic         RBPMS          0.0471379   2.564619           Down
  \#N/A                   chr4         −        Intronic       GPR125         0.0314876   1.6460992          Down
  hsa_circ_0053070        chr2         \+       Exonic         HADHB          0.0223274   1.8756974          Down
  hsa_circ_0023730        chr11        −        Exonic         INTS4          0.0474224   1.644243           Down
  hsa_circ_0038644        chr16        \+       Exonic         PRKCB          0.0050378   1.5424169          Down
  hsa_circ_0064557        chr3         −        Exonic         SATB1          0.0344432   1.6859964          Down
  \#N/A                   chr1         −        Exonic         PDE4DIP        0.0220458   1.6090404          Down
  hsa_circ_0069681        chr4         −        Exonic         FRYL           0.0374764   1.6037813          Down
  hsa_circ_0006891        chr11        \+       Exonic         PPFIBP2        0.0257878   1.6666432          Down
  hsa_circ_0021827        chr11        −        Exonic         PHF21A         0.0249203   1.589884           Down
  hsa_circ_0001122        chr2         \+       Exonic         FARP2          0.0045619   1.5731657          Down
  hsa_circ_0013607        chr1         −        Exonic         RSBN1          0.0376341   2.0202019          Down
  hsa_circ_0005967        chr10        −        Exonic         KCNMA1         0.0160756   1.6827265          Down
  hsa_circ_0000446        chr12        −        Exonic         TAOK3          0.0325774   1.6013056          Down
  hsa_circ_0070857        chr4         \+       Exonic         KIAA1109       0.0418502   1.8511599          Down
  hsa_circ_0007590        chr13        −        Exonic         LATS2          0.007774    1.7207037          Down
  hsa_circ_0006629        chr11        −        Exonic         PICALM         0.0191864   1.750488           Down
  hsa_circ_0001640        chr6         −        Exonic         EPB41L2        0.0482272   2.8931722          Down
  hsa_circ_0066378        chr3         \+       Exonic         ABHD6          0.0429032   2.3329893          Down
  hsa_circ_0025711        chr12        −        Exonic         TM7SF3         0.0253257   2.0133054          Down
  hsa_circ_0023865        chr11        −        Exonic         CCDC90B        0.0386574   1.6774031          Down
  hsa_circ_0000077        chr1         −        Overlapping    TM2D1          0.0236483   1.5061897          Down
  hsa_circ_0005527        chr11        −        Exonic         FCHSD2         0.02705     2.2952095          Down
  hsa_circ_0030042        chr13        −        Exonic         FOXO1          0.0174801   2.1639648          Down
  hsa_circ_0007201        chr15        \+       Exonic         IQGAP1         0.0248831   1.7816364          Down
  \#N/A                   chr11        \+       Exonic         DLAT           0.0309512   1.5343122          Down
  \#N/A                   chr4         −        Exonic         NR3C2          0.0476049   1.5305334          Down
  hsa_circ_0084137        chr8         −        Exonic         RNF170         0.0164973   2.1286009          Down
  hsa_circ_0013162        chr1         −        Exonic         EVI5           0.0337218   2.6161063          Down
  hsa_circ_0037969        chr16        −        Exonic         PARN           0.0354487   1.5344047          Down
  hsa_circ_0077765        chr6         \+       Exonic         RNF217         0.0169759   1.5605383          Down
  \#N/A                   chr11        \+       Exonic         TEAD1          0.0014024   1.81072            Down
  hsa_circ_0035376        chr15        \+       Exonic         PIGB           0.0174      1.5311146          Down
  hsa_circ_0000389        chr12        \+       Over-lapping   FGD4           0.0319098   1.5397315          Down
  hsa_circ_0030281        chr13        −        Exonic         DLEU2          0.0245441   2.2986061          Down
  \#N/A                   chr16        \+       Intronic       MT2A           0.0025438   2.8617763          Down

[^1]: Contributed equally
